SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cancer - Side effect drugs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who started this subject5/18/2002 2:16:06 PM
From: John McCarthy   of 57
 
[2000]-[BNP7787]-[BioNumerik Pharmaceuticals, Inc. (Private)]

BioNumerik Pharmaceuticals, Inc. (Private)

BioNumerik Pharmaceuticals, Inc., based in San Antonio, TX, focuses on mechanism-based drug discovery, analysis of drug targeting, metabolism and drug delivery at the atomic level to optimize molecular leads. BioNumerik uses Cray supercomputers and sophisticated proprietary software to simulate how compounds will work once inside the body. BioNumerik already has generated a portfolio of 10 small-molecule agents for the treatment of cancer and has three compounds in the clinic. BioNumerik's BNP7787 is a novel chemoprotecting agent that received Fast Track Designation and will be in Phase III clinical trials by year end. BioNumerik's MDAM, in Phase I in the United States, is an anticancer agent designed for reducing toxicity and drug resistance and has demonstrated antitumor activity against several common solid tumors. Karenitecin, also in Phase I pediatric clinical trials in the United States and scheduled to initiate Phase II trials in gliomas and lung cancer by year end, is a novel fourth generation camptothecin that appears to be substantially less sensitive to multi-drug resistance (MDR/MRP) and camptothecin type drug resistance mechanisms.

noonanrusso.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News